CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively ...
Research demonstrates that platform technologies generate therapeutic molecules for selective delivery of immune activating signals, such as IL-2, to disease-relevant T cells, hence avoiding systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results